Skip to main content

lidocaine / prilocaine (Senstend®)

 

Following non-submission

AWMSG advice

Status: Not endorsed (Statement of Advice)

In the absence of a submission from the holder of the marketing authorisation, lidocaine/prilocaine (Senstend®) cannot be endorsed for use within NHS Wales for the treatment of primary premature ejaculation in adult men

 Statement of Advice (SOA): lidocaine/prilocaine (Senstend) 4384 (PDF, 97Kb)

Medicine details

Medicine name lidocaine / prilocaine (Senstend®)
Formulation 150 / 50 mg/ml cutaneous solution
Reference number 4384
Indication

For the treatment of primary premature ejaculation in adult men

Company Plethora Solutions Holdings PLC
BNF chapter Obstetrics, gynaecology & urinary tract disorders
Assessment type Non-submission
Status Not endorsed (Statement of Advice)
Date of issue 16/06/2020
Follow AWTTC: